Inclusion criteria :<br/><br/>        I 01. Diagnosis of histologically or cytologically proven prostate adenocarcinoma, that is<br/>        resistant to hormone therapy and previously treated with a docetaxel-containing regimen.<br/><br/>        I 02. Patient must have either measurable or non-measurable disease. I 03. Received prior<br/>        castration by orchiectomy and/or Luteinizing Hormone-Releasing Hormone (LH-RH) agonist<br/>        with or without antiandrogen, antiandrogen withdrawal, monotherapy with estramustine, or<br/>        other hormonal agents.<br/><br/>        I 04. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 - 2 (ie, patient<br/>        must be ambulatory, capable of all self-care, and up and about more than 50% of waking<br/>        hours).<br/><br/>        I 05. Age ≥18 years (or country's legal age of majority if the legal age is > 18 years).<br/><br/>        Exclusion criteria:<br/><br/>        E 01. Previous treatment with mitoxantrone or cabazitaxel. E 02. Prior isotope therapy or<br/>        radiotherapy to ≥30% of bone marrow. In case of prior isotope therapy 12 weeks must have<br/>        elapsed prior to first study drug administration.<br/><br/>        E 03. Adverse events (excluding alopecia and those listed in the specific exclusion<br/>        criteria) from any prior anticancer therapy of grade >1(National Cancer Institute Common<br/>        Terminology Criteria [NCI CTCAE] v4.03) at the time of randomization.<br/><br/>        E 04. Prior surgery, radiation, chemotherapy, or other anti-cancer therapy within 4 weeks<br/>        prior to enrollment in the study.<br/><br/>        E 05. Prior malignancy. Adequately treated basal cell or squamous cell skin or superficial<br/>        (pTis, pTa, and pT1) bladder cancer are allowed, as well as any other cancer for which<br/>        chemotherapy has been completed ≥ 5 years ago and from which the patient has been<br/>        disease-free for ≥ 5 years.<br/><br/>        E 06. Participation in another clinical trial and any concurrent treatment with any<br/>        investigational drug within 30 days prior to randomization.<br/><br/>        E 07. Known brain or leptomeningeal involvement. E 08. Other concurrent serious illness or<br/>        medical conditions E 09. Uncontrolled cardiac arrhythmias, angina pectoris, and/or<br/>        hypertension. History of congestive heart failure (NYHA III or IV) or myocardial<br/>        infarction within last 6 months is also not allowed.<br/><br/>        E 10. Any severe acute or chronic medical condition which could impair the ability of the<br/>        patient to participate to the study or to comply with the study procedures or interfere<br/>        with interpretation of study results.<br/><br/>        E 11. Absence of signed and dated Institutional Review Board (IRB)-approved patient<br/>        informed consent form prior to enrollment into the study.<br/><br/>        E 12. Patients with reproductive potential who do not agree to use accepted and effective<br/>        method of contraception during the study treatment period. The definition of "effective<br/>        method of contraception" will be based on the Investigator's judgment. Patients' Partners<br/>        of childbearing potential (unless surgically sterile, post menopausal or for another<br/>        reason have no chance of becoming pregnant) not protected by highly effective<br/>        contraceptive method of birth control as defined for contraception in the Informed Consent<br/>        Form and /or in a local protocol addendum.<br/><br/>        E 13. History of hypersensitivity to docetaxel, or polysorbate 80. E 14. Inadequate organ<br/>        and bone marrow function. E 15. Contraindications to the use of corticosteroid treatment.<br/>        E 16. Symptomatic peripheral neuropathy grade > 2 (National Cancer Institute Common<br/>        Terminology Criteria [NCI CTCAE] v.4.03).<br/><br/>        The above information is not intended to contain all considerations relevant to a<br/>        patient's potential participation in a clinical trial.<br/>